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A persistently low HBV DNA level is a predictor of spontaneous HBsAg clearance in
patients with chronic hepatitis B
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Bckground/aim: The incidence and predictors of spontaneous hepatitis B surface-antigen (HBsAg) seroclearance in patients with
chronic hepatitis B virus (HBV) were evaluated.
Materials and methods: A total of 1427 patients with chronic HBV infection, who were followed between 1994 and 2013, were
investigated in this retrospective study. All data were extracted from patient files.
Results: Spontaneous HBsAg seroclearance occurred in 84 patients during 8798 person-years of follow-up. The patients were categorized
into 3 groups at follow-up based on HBV DNA features as continuously <100 copies/mL (Group A), 0–10,000 copies/mL (Group B),
and 0 to >10,000 copies/mL (Group C). Alanine aminotransferase features in the 2 groups were categorized as continuously normal
(<40 U/L) and 0 to >40 U/L. Spontaneous HBsAg seroclearance was seen primarily in patients with Group A HBV DNA features, and
continuously low HBV DNA values were the main predictor of HBsAg seroclearance (P < 0.001).
Conclusion: These results suggest that a continuously low viral load is the most important factor affecting spontaneous HBsAg
seroclearance.
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1. Introduction
Chronic hepatitis B virus (HBV) infection is a serious
public health problem due to its worldwide prevalence
and potential to cause other adverse consequences, such
as cirrhosis and hepatocellular carcinoma (HCC) (1).
More than 240 million patients have chronic (long-term)
liver infections. Approximately 600,000 patients die every
year due to the acute or chronic consequences of HBV.
Several epidemiological studies have shown that hepatitis
B surface-antigen (HBsAg) seropositivity is an important
risk factor for further disease, including cirrhosis and
HCC (1). Current antiviral therapies result in relatively
low HBsAg clearance rates of 0.5%–2.3% (2). Spontaneous
HBsAg seroclearance in untreated individuals is a
relatively rare event, particularly in highly endemic areas.
Previous studies have found annual seroclearance rates of
0.5%–1.4% (2). Predictors of HBsAg seroclearance include
old age, HBeAg seronegativity, male sex, HBV genotype B,
and low serum HBV-DNA level (<105 copies/mL) (3). We
retrospectively evaluated the incidence and determinants
of spontaneous HBsAg seroclearance in patients with
* Correspondence: sebnemozkoren@yahoo.com
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chronic HBV, who were followed up at the Infectious
Diseases and Clinical Microbiology Department of a
tertiary-care hospital.
2. Materials and methods
2.1. Patient data source
A total of 2625 patients were evaluated from 1994 to 2013,
and 1427 patients (aged 13–86 years) were included. All
data were extracted from patient files. Tests on serum
HBsAg, HBeAg, anti-HBe, anti-HBs serum HBV-DNA,
and alanine aminotransferase (ALT) levels were measured
using commercial kits. HBsAg, anti-HBsAb, HBeAg,
anti-HBeAb, anti-HCV, and anti-Delta were measured
with an autoanalyzer using commercial reagents. HBV
DNA was assayed by real-time polymerase chain reaction
(RT-PCR) assay using the Artus HBV RG PCR Kit with
the QIAGEN Rotor-Gene Q 6000 device (Valencia, CA,
USA). The analytical lower detection limit of the assay
was 3.8 IU/mL (constant: 8.2 to conversion copy: 31.4, P
= 0.05). Ultrasounds were performed regularly for HCC
surveillance.
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2.2. Inclusion and exclusion criteria
Patient inclusion criteria for the study were: 1) HBsAg,
HBeAg, anti-HBe, anti-HBs, HBV DNA, and ALT
monitoring at least once annually, 2) 3 HBV DNA tests
with PCR, and 3) follow-up duration of >1 year.
Exclusion criteria were: 1) antiviral therapy, 2)
immunosuppressive therapy and/or immunosuppressive
status, and 3) coinfection with a Delta virus or HCV.
2.3. Patient classification
We observed various HBV DNA and ALT values at followup in the patients with HBV. Because of these features, the
patients were classified not as unique values but rather as
spectral values. The first group was defined as continuously
<100 copies HBV DNA/mL band (Group A), the second
group as 0–10,000 copies/mL band (Group B), and the
third group as 0 to >10,000 copies/mL (Group C). Similarly,
the patients were classified according to ALT values as <40
U/L and >40 U/L. We considered that the 0–100 copies/
mL category represented continuously low HBV DNA, the
0–10,000 category represented a heterogeneous group, and
the 0 to >10,000 copies/mL category represented patients
who had histologic active disease potential.
2.4. Statistical analysis
All data were extracted from the patients’ files
retrospectively. Statistical analysis was conducted using
SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Comparison of
continuous variables was performed with Student’s t-test.
The log-rank test with adjusted Kaplan–Meier time curve
analyses was performed to determine the significance of
the predictive factors (age, sex, HBV DNA, and ALT) for
loss of HBsAg. Significant variables were analyzed with
the Cox regression model. The estimated probability
curves for loss of HBsAg were calculated according to
the Cox regression model, adjusted for the influence of
the significant variables (Figure 1). Data are expressed as
means ± standard deviation (SD), ranges, and percentages
(%) where appropriate. All statistical tests were two-sided,
and P < 0.05 was considered to indicate significance.
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3. Results
The patients (660 [46.3%] females and 767 [53.7%] males)
were aged 13–86 years, with a total of 8798 person-years
of follow up. The mean follow-up period was 6.17 ± 4.13
years (range: 2–18 years). The mean age at the beginning
of the follow-up was 37.13 ± 12.21 years. According to the
questionnaire and blood test results, 647 family members
(45.3%) and 167 mothers (11.7%) of patients had chronic
HBV or had developed immunity. The DNA and ALT
levels in all patients are shown in Table 1. An ALT level
of <40 IU/mL was detected in 1145 patients (80.2%). The
prevalence of the HBV DNA level categories of 0–100,
0–10,000, and 0 to >10,000 IU/mL were 22.6%, 47.7%, and
29.6%, respectively.
Eighty-four (33 [39.3%] females and 51 (60.7%) males)
patients (5.7%) showed HBsAg seroclearance during the
follow-up period. The DNA and ALT levels in all patients
are shown in Table 2. HBsAg seroclearance rates are shown
in Figure 1.
Among the 84 patients who had spontaneous HBsAg
seroclearance, 73% had inactive disease with persistently
<100 copies HBV DNA/mL and 0–40 IU/L ALT. One
patient was HBeAg-positive (1.2%) at first admission.
The relationships between HBsAg seroclearance, age,
male sex, HBV DNA, and ALT levels were investigated.
Of these parameters, only 0–100 copies HBV DNA/mL
(P = 0.000) and age at beginning of follow-up (P = 0.009)
were significantly correlated with spontaneous HBsAg
seroclearance. The HBV DNA categories were a unique
predictor of loss of HBsAg in the Cox regression analysis.
The cumulative probability of HBsAg loss during the
14-year follow-up period is shown in Figure 2. A total
of 43% of patients were in the 0–100 copies HBV DNA/
mL category. No patients with spontaneous HBsAg
seroclearance developed cirrhosis or HCC during the
follow-up period. Fifty patients (59.2%) with spontaneous
HBsAg seroclearance were anti-HBs-positive.
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Figure 1. Hepatitis B virus surface antigen (HBsAg) seroclearance rate according to age.
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Table 1. Hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) classifications and number of patients.
ALT 0–40, n (%)

ALT 0 to >40, n (%)

Total, n (%)

HBV DNA <100, n (%)

286 (20%)

37 (2.6%)

323 (22.6%)

HBV DNA 0–10,000, n (%)

588 (41.2%)

93 (6.5%)

681 (47.7%)

HBV DNA 0 to >10,000, n (%)

271 (19%)

152 (10.7%)

423 (29.6%)

Total, n (%)

1145 (80.2%)

282 (19.8%)

1427 (100%)

Table 2. Hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) classifications of all patients who achieved spontaneous
hepatitis B virus surface antigen (HBsAg) seroclearance.
DNA (copies/mL)

ALT 0–40, n (%)

ALT 0 to >40, n (%)

Total, n (%)

HBV DNA <100, n (%)

62 (73.8%)

4 (4.8%)

66 (78.6%)

HBV DNA 0–10,000, n (%)

9 (10.8%)

5 (6%)

14 (16.7%)

HBV DNA 0 to >10,000, n (%)

0 (0%)

4 (4.8%)

4 (4.8%)

Total, n (%)

71 (84.6%)

13 (15.5%)

84 (100%)

Cumulative probability of HBsAg loss

HBVDNA categories
(copy/mL)
<100
<10,000
>10,000

43%

6%
3%

Figure 2. Cumulative probability of hepatitis B virus surface antigen (HBsAg) loss according to HBV DNA
level during the follow-up period.

Forty-eight (3.4%) patients were HBeAg-positive at first
admission, 31 (64.5%) were persistently HBeAg-positive,
and 3 (6.2%) were anti-HBe-positive simultaneously.
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Seventeen patients (35.47%) lost the HBeAg antigen. Of
these, 13 (27%) developed anti-HBe. One (1.1%) patient
who was HBeAg-positive achieved HbsAg seroclearance.
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4. Discussion
HBV infection is an important cause of acute and chronic
liver disease worldwide. Patients with chronic HBV
infection are at increased risk of developing cirrhosis,
hepatic decompensation, and HCC. It is estimated that the
lifetime risk of developing complications is 25%–40% in
HBV carriers who acquire the virus early in life. Providing
clear information about disease progression is the most
important criterion in terms of patient safety (4).
HBsAg seroclearance is the ultimate goal of immune
clearance. Spontaneous HBsAg seroclearance is defined as
loss of serum HBsAg on two occasions at least 6 months
apart. Maintaining the absence of serum HBsAg (annual
incidence: 1%–2%) at the last visit is rare during the
natural history of a chronic HBV infection (3,5). In this
study, the cumulative probability of losing HBsAg during
a 14-year follow-up was 43% for Group A. The cumulative
probability of spontaneous HBsAg seroclearance increased
from 8.1% to 24.9% after 10 years, and to 44.7% after 20
years in a study by Chu and Liaw (6).
In the present study, HBsAg seroclearance developed
in 5.8% of all patients who met the inclusion criteria. The
relationships between HBsAg seroclearance and age, male
sex, HBV DNA, and ALT levels were investigated; however,
only HBV DNA was statistically significant.
HBsAg seroclearance rates according to age are 8.3%
for 41–50 years, 6.9% for 51–60 years, and 6.2% for >60
years. The epidemiological features of HBV infection in
Turkey are similar to those in Mediterranean and Middle
Eastern countries. The most common transmission route
for infection in this region is horizontal transmission
during early childhood and adolescence (7). This finding
may be attributed to the long-term follow-up of these
patients.
Loss of HBeAg in HBV carriers is a sign of remission of
hepatitis and suppression of HBV replication (3). However,
applying a sensitive method to detect serum HBV showed
that HBV can continuously or intermittently replicate,
even in HBeAg-negative patients (8).
During the follow up, clinicians observed more than
one HBV DNA and ALT value for the patients with chronic
HBV and defined the disease categories as inactive carrier
state, active disease, and other serious complications
that should be treated, such as cirrhosis or HCC (9,10).
As a result of this spectral character, the patients were
categorized as spectral. Initial HBV DNA level was not
associated with loss of HBsAg in some previous studies;
nevertheless, if patients are evaluated according to spectral
character, HBV DNA is the most important feature (5).
Although major guidelines define the inactive chronic
HBV carrier state as anti-HBe-positive, these patients have
normal ALT and HBV DNA of <2000 IU/mL (∼10,000

copies/mL) levels. Although most inactive carriers remain
stable throughout their life and some eventually achieve
HBsAg seroclearance, up to 30% of these inactive carriers
may encounter reactivation of HBV and develop HBeAgnegative chronic hepatitis (9,10). According to European
Association for the Study of the Liver guidelines, some
inactive carriers may have HBV DNA levels of >10,000
copies/mL (usually <100,000 copies/mL) accompanied
by a persistently normal ALT level, but this definition
can hide cirrhotic disease (9). Some patients classified as
inactive carriers have differing fibrotic activity (8). In this
study, most patients had heterogeneous features. A total
of 681 patients (47.7%) had a HBV DNA level of 0–10,000
copies/mL, and 271 (19%) had 0 to >10,000 copies/mL
DNA and a 0–40 IU/mL ALT level. These groups included
66.7% of all patients. Our results show that continuously
low HBV DNA level not only predicted HBsAg loss but
also identified patients with inactive disease.
Most studies have not associated sex with the incidence
of HBsAg seroclearance, as we found, with the exception
of two studies conducted in Alaska and Taiwan. In the
study conducted in Alaska, female carriers were more
likely to clear HBsAg than males. In contrast, the study in
Taiwan showed that HBsAg seroclearance was significantly
more common in male carriers in univariate analysis,
although the difference became marginally significant in
multivariate analysis (3).
The antigenic determinants of HBsAg are classified
into 4 subtypes or are based on serotype. The subtypes are
divided into subdivisions within 9 serotypes. Eight HBV
genotypes (A–H) have been identified, and the roles of
the genotypes have been investigated in several studies.
HBsAg seroclearance is more likely in patients with
genotype B than in those with genotype C, and more likely
in genotype A than in genotype D (3). Several genotype
studies on patients with chronic HBV have been conducted
in Turkey. Genotype D is the most prevalent genotype in
patients with HBV in Turkey (11).
The disappearance of HBsAg and the appearance of
anti-HBs in sera indicate HBV clearance (12). Several
studies have reported that serum HBV DNA may still be
detectable by PCR and more often in the liver (8,9). The
prognosis improves in carriers that clear HBsAg, although
HCC has been reported years after HBsAg clearance,
particularly in older patients or in those who progressed
to cirrhosis before clearing HBsAg (3). None of the
patients who achieved spontaneous HBsAg seroclearance
developed cirrhosis or HCC during the follow-up in our
study. However, we found that serum HBV DNA was not
detectable in patients who lost HBsAg, even in those who
did not develop detectable anti-HBs. The detectable antiHB rate was 59.2% in this study.
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In conclusion, we showed that a continuously low
HBV DNA level was a significant predictor of spontaneous
HBsAg seroclearance. Patients with a continuously low
HBV DNA level may have inactive disease.
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